跳至主要内容
临床试验/NCT01672151
NCT01672151已完成不适用

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

First Affiliated Hospital of Suzhou Medical College1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2011年11月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
35
试验地点
1

研究概览

简要总结

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

详细描述

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Clinical diagnoses of idiopathic thrombocytopenic purpura
  • Hormone and immune suppression, splenectomy is invalid

排除标准

  • patients had a bad tolerance to rapamycin
  • platelet counts < 10*10E9/L during the treatment of rapamycin

研究者

发起方
First Affiliated Hospital of Suzhou Medical College
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhaoyue Wang

Jiangsu Institute of hematology

First Affiliated Hospital of Suzhou Medical College

研究点 (1)

Loading locations...

相似试验